Concepedia

Jeffrey Hartung

JH

5

Publications

383

Citations

5

H-Index

2011

Active since

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

Jeffrey Hartung is an author at Bristol-Myers Squibb (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2011–2017

5

Publications

5

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

Jeffrey A. Cohen, Douglas L. Arnold, Amit Bar‐Or et al. · The Lancet Neurology · 2016 · 176 citations

, , +7

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach et al. · The Journal of Clinical Pharmacology · 2017 · 106 citations · Full text

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Jonathan Q. Tran, Jeffrey Hartung, Allan Olson et al. · Clinical Pharmacology in Drug Development · 2017 · 58 citations · Full text

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Cindy‐ann Tompkins et al. · Clinical Pharmacology in Drug Development · 2017 · 26 citations · Full text

Pharmacodynamics, Pharmacokinetics, and Safety of AM211: A Novel and Potent Antagonist of the Prostaglandin D<sub>2</sub> Receptor Type 2

Gretchen Bain, Christopher D. King, Jason Brittain et al. · The Journal of Clinical Pharmacology · 2011 · 17 citations

, , +14

Rows per page

1–5 of 5